Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF)
$ 0.1705 -0.0095 (-5.28%) Market Cap: 54.42 Mil Enterprise Value: 32.43 Mil PE Ratio: 0 PB Ratio: 2.45 GF Score: 29/100

Paradigm Biopharmaceuticals Ltd Investor Webinar Transcript

Oct 04, 2022 / NTS GMT
Release Date Price: $0.7873
Unidentified Participant

Thank you for standing by, and welcome to the Paradigm Biopharmaceuticals Top-line Data Investor Webinar, discussing the announcement lodged with the ASX earlier this morning. Firstly, an apology for the short notice between the announcement lodgment and this session. We are awaiting approval from the ASX to have the announcement lodged.

And for anyone who has missed a live session now, this is being recorded. And the replay will be available very soon after the end of the webinar. All participants today are in listen-only mode. There will be a slide presentation lasting for approximately 20 to 25 minutes.

Please note that today's session is designed to give an overview of the new data announcement. And we would ask for any questions to be referred to the Investor Relations at paradigmbiopharma.com e-mail address, which can be found at the bottom of all announcements. And these will be responded to after the webinar.

In terms of introductions appearing on behalf of Paradigm today, we have CEO, Marco Polizzi; Chief Medical Officer, Dr. Donna Skerrett; and Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot